Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 8, 2008, Pages 3173-3178

  Naylor, Jennifer C ^a,b   Hulette, Christine M ^b   Steffens, David C ^b   Shampine, Lawrence J ^a,b   Ervin, John F ^b   Payne, Victoria M ^a,b   Massing, Mark W ^a   Kilts, Jason D ^a,b   Strauss, Jennifer L ^a,b   Calhoun, Patrick S ^a,b   Calnaido, Rohana P ^a,b   Blazer, Daniel G ^b   Lieberman, Jeffrey A ^c   Madison, Roger D ^a,b   Marx, Christine E ^a,b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROSTEROID; PRASTERONE; PREGNENOLONE;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DATA ANALYSIS; DRUG CEREBROSPINAL FLUID LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MASS FRAGMENTOGRAPHY; MEDICAL RESEARCH; NEUROPATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANK SUM TEST; STATISTICAL SIGNIFICANCE; TEMPORAL CORTEX; UNIVERSITY HOSPITAL;

EID: 49249123698     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1229     Document Type: Article

References (47)

1. Marx CE, Trost WT, Shampine LJ, Stevens RD, Hulette CM, Steffens DC, Ervin JF, Butterfield MI, Blazer DG, Massing MW, Lieberman JA 2006 The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol Psychiatry 60:1287-1294
2. Marx CE, Steffens DC, Blazer DG, Ervin JF, Hulette CM, Massing MW, Butterfield MI, Lieberman JA, Shampine LJ Deficits in the GABAergic neuroactive steroid allopregnanolone in Alzheimer's disease and relevance to neuropathological disease stage: investigations in temporal cortex. Proc 44th Annual Meeting of the American College of Neuropsychopharmacology, Wailkoloa, Hawaii, 2005, p S79 (Abstract 7)
3. Brown RC, Han Z, Cascio C, Papadopoulos V 2003 Oxidative stress-mediated DHEA formation in Alzheimer's disease pathology. Neurobiol Aging 24:57-65
4. Kim SB, Hill M, Kwak YT, Hampl R, Jo DH, Morfin R 2003 Neurosteroids: cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics. J Clin Endocrinol Metab 88:5199-5206
5. Vallee M, Mayo W, Le Moal M 2001 Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res Brain Res Rev 37:301-312
6. Gursoy E, Cardounel A, Kalimi M 2001 Pregnenolone protects mouse hippocampal (HT-22) cells against glutamate and amyloid β protein toxicity. Neurochem Res 26:15-21
7. Marx CE, Jarskog LF, Lauder JM, Gilmore JH, Lieberman JA, Morrow AL 2000 Neurosteroid modulation of embryonic neuronal survival in vitro following anoxia. Brain Res 871:104-112
8. Marx CE, Shampine LJ, Duncan GE, VanDoren MJ, Grobin AC, Massing MW, Madison RD, Bradford DW, Butterfield MI, Lieberman JA, Morrow AL 2006 Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? Pharmacol Biochem Behav 84:598-608
9. Hulette CM, Welsh-Bohmer KA, Crain B, Szymanski MH, Sinclaire NO, Roses AD 1997 Rapid brain autopsy. The Joseph and Kathleen Bryan Alzheimer's Disease Research Center experience. Arch Pathol Lab Med 121:615-618
10. Braak H, Braak E 1991 Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239-259
11. Geddes JW, Tekirian TL, Soultanian NS, Ashford JW, Davis DG, Markesbery WR 1997 Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging 18:S99-S105
12. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, Jicha GA, Ivnik RJ, Smith GE, Tangalos EG, Braak H, Kokmen E 2006 Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 63:665-672
13. Morley JE, Kaiser F, Raum WJ, Perry 3rd HM, Flood JF, Jensen J, Silver AJ, Roberts E 1997 Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci USA 94:7537-7542
14. Roberts E 1995 Pregnenolone - from Selye to Alzheimer and a model of the pregnenolone sulfate binding site on the GABAA receptor. Biochem Pharmacol 49:1-16
15. 25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience. 83:413-428
16. Brown RC, Cascio C, Papadopoulos V 2000 Pathways of neurosteroid biosynthesis in cell lines from human brain: regulation of dehydroepiandrosterone formation by oxidative stress and β-amyloid peptide. J Neurochem 74:847-859
17. Counterman AE, D'Onofrio TG, Andrews AM, Weiss PS 2006 A physical model of axonal damage due to oxidative stress. Proc Natl Acad Sci USA 103:5262-5266
18. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP 2004 Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 101:2070-2075
19. Korolainen MA, Goldsteins G, Nyman TA, Alafuzoff I, Koistinaho J, Pirttila T 2006 Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging 27:42-53
20. Mariani E, Polidori MC, Cherubini A, Mecocci P 2005 Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 827:65-75
21. Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, Cohn JS, Christen Y, Davignon J, Quirion R, Poirier J 1999 Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med 27:544-553
22. Kimonides VG, Spillantini MG, Sofroniew MV, Fawcett JW, Herbert J 1999 Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Neuroscience 89:429-436
23. Bastianetto S, Ramassamy C, Poirier J, Quirion R 1999 Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Brain Res Mol Brain Res 66:35-41
24. Tunez I, Munoz MC, Montilla P 2005 Treatment with dehydroepiandrosterone prevents oxidative stress induced by 3-nitropropionic acid in synaptosomes. Pharmacology 74:113-118
25. Cardounel A, Regelson W, Kalimi M 1999 Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proc Soc Exp Biol Med 222:145-149
26. Kurata K, Takebayashi M, Morinobu S, Yamawaki S 2004 β-estradiol, dehydroepiandrosterone, and dehydroepiandrosterone sulfate protect against N-methyl-D-aspartate-induced neurotoxicity in rat hippocampal neurons by different mechanisms. J Pharmacol Exp Ther 311:237-245
27. Karishma KK, Herbert J 2002 Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci 16:445-453
28. Suzuki M, Wright LS, Marwah P, Lardy HA, Svendsen CN 2004 Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci USA 101:3202-3207
29. Meunier J, Maurice T 2004 Beneficial effects of the σ1 receptor agonists igmesine and dehydroepiandrosterone against learning impairments in rats prenatally exposed to cocaine. Neurotoxicol Teratol 26:783-797
30. Alhaj HA, Massey AE, McAllister-Williams RH 2006 Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study. Psychopharmacology (Berl) 188:541-551
31. Wolkowitz OM, Kramer JH, Reus VI, Costa MM, Yaffe K, Walton P, Raskind M, Peskind E, Newhouse P, Sack D, De Souza E, Sadowsky C, Roberts E 2003 DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Neurology 60:1071-1076
32. Olney JW, Wozniak DF, Farber NB 1998 Glutamate receptor dysfunction and Alzheimer's disease. Restor Neurol Neurosci 13:75-83
33. Bergeron R, de Montigny C, Debonnel G 1996 Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via σ receptors. J Neurosci 16:1193-1202
34. Imamura M, Prasad C 1998 Modulation of GABA-gated chloride ion influx in the brain by dehydroepiandrosterone and its metabolites. Biochem Biophys Res Commun 243:771-775
35. Weill-Engerer S, David JP, Sazdovitch V, Liere P, Schumacher M, Delacourte A, Baulieu EE, Akwa Y 2003 In vitro metabolism of dehydroepiandrosterone (DHEA) to 7α-hydroxy-DHEA and Δ5-androstene- 3β,17β-diol in specific regions of the aging brain from Alzheimer's and non-demented patients. Brain Res 969:117-125
36. Yau JL, Rasmuson S, Andrew R, Graham M, Noble J, Olsson T, Fuchs E, Lathe R, Seckl JR 2003 Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer's disease. Neuroscience 121:307-314
37. Kimonides VG, Khatibi NH, Svendsen CN, Sofroniew MV, Herbert J 1998 Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci USA 95:1852-1857
38. Flood JF, Morley JE, Roberts E 1992 Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci USA 89:1567-1571
39. Papadopoulos V 1993 Peripheral-type benzodiazepine/diazepam binding inhibitor receptor: biological role in steroidogenic cell function. Endocr Rev 14:222-240
40. Diorio D, Welner SA, Butterworth RF, Meaney MJ, Suranyi-Cadotte BE 1991 Peripheral benzodiazepine binding sites in Alzheimer's disease frontal and temporal cortex. Neurobiol Aging 12:255-258
41. Owen F, Poulter M, Waddington JL, Mashal RD, Crow TJ 1983 [3H]R05-4864 and [3H]flunitrazepam binding in kainate-lesioned rat striatum and in temporal cortex of brains from patients with senile dementia of the Alzheimer type. Brain Res 278:373-375
42. Marx CE, Shampine LJ, Khisti RT, Trost WT, Bradford DW, Grobin AC, Massing MW, Madison RD, Butterfield MI, Lieberman JA, Morrow AL 2006 Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Pharmacol Biochem Behav 84:609-617
43. Serra M, Pisu MG, Muggironi M, Parodo V, Papi G, Sari R, Dazzi L, Spiga F, Purdy RH, Biggio G 2001 Opposite effects of short- versus long-term administration of fluoxetine on the concentrations of neuroactive steroids in rat plasma and brain. Psychopharmacology (Berl) 158:48-54
44. Griffin LD, Mellon SH 1999 Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 96:13512-13517
45. Trauger JW, Jiang A, Stearns BA, LoGrasso PV 2002 Kinetics of allopregnanolone formation catalyzed by human 3α-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry 41:13451-13459
46. Marx CE, Trost WT, Shampine L, Behm FM, Giordano LA, Massing MW, Rose JE 2006 Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers. Psychopharmacology (Berl) 186:462-472
47. Mendelson JH, Sholar MB, Goletiani N, Siegel AJ, Mello NK 2005 Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men. Neuropsychopharmacology 30:1751-1763